1423700-75-7

Upstream product

• 1396007-85-4 1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid methyl ester 
• 873011-70-2 methyl 1-(4'-hydroxybiphenyl-4-yl)cyclopropane-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 1423700-73-5 methyl 1-[4-(4-bromophenyl)phenyl]cyclopropanecarboxylate 
• 638220-35-6 1-(4-bromophenyl)-cyclopropanecarboxylic acid methyl ester 
• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 16532-79-9 4-Bromophenylacetonitrile 

Downstream Products

• 1423692-16-3 C₂₉H₂₆N₂O₄S 
• 1423689-69-3 C₃₀H₂₇ClN₂O₄S 
• 1402466-49-2 1-[4'-(5-amino-1-methyl-1H-pyrazol-4-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid methyl ester 
• 1396007-17-2 (R)-1-{4'-[5-(sec-butoxycarbonylamino)-1-methyl-1H-pyrazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid 

Relevant academic research and scientific papers

LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS

A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.

Speciation control during Suzuki-Miyaura cross-coupling of haloaryl and haloalkenyl MIDA boronic esters

Boronic acid solution speciation can be controlled during the Suzuki-Miyaura cross-coupling of haloaryl N-methyliminodiacetic acid (MIDA) boronic esters to enable the formal homologation of boronic acid derivatives. The reaction is contingent upon control of the basic biphase and is thermodynamically driven: temperature control provides highly chemoselective access to either BMIDA adducts at room temperature or boronic acid pinacol ester (BPin) products at elevated temperature. Control experiments and solubility analyses have provided some insight into the mechanistic operation of the formal homologation process.

Chemoselective Boronic Ester Synthesis by Controlled Speciation

Control of boronic acid solution speciation is presented as a new strategy for the chemoselective synthesis of boronic esters. Manipulation of the solution equilibria within a cross-coupling milieu enables the formal homologation of aryl and alkenyl boron

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

SUBSTITUTED PYRAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis